| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
26,510,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rain Therapeutics is a late-stage precision oncology company developing therapies that target oncogenic drivers for which Co. is able to genetically select patients most likely to benefit. Co.'s primary product candidate, milademetan, is a small molecule, oral inhibitor of mouse double minute 2, which may be oncogenic in various cancers. In addition to milademetan, Co. is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,372,418 |
4,244,869 |
| Total Buy Value |
$0 |
$0 |
$1,437,794 |
$18,372,213 |
| Total People Bought |
0 |
0 |
1 |
5 |
| Total Buy Transactions |
0 |
0 |
6 |
12 |
| Total Shares Sold |
0 |
173,973 |
1,168,973 |
1,168,973 |
| Total Sell Value |
$0 |
$209,413 |
$1,453,163 |
$1,453,163 |
| Total People Sold |
0 |
1 |
2 |
2 |
| Total Sell Transactions |
0 |
3 |
4 |
4 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Edelman Joseph |
10% Owner |
– – • |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
I/I |
1,987,019 |
1,987,019 |
|
- |
|
| Mva Investors, Llc |
Director |
– • • |
2021-04-27 |
4 |
B |
$17.00 |
$17,425,000 |
I/I |
1,025,000 |
1,175,000 |
2.25 |
- |
|
| Doebele Robert |
EVP, Chief Scientific Officer |
• – – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,932 |
467,937 |
|
- |
|
| Lewis Joseph |
10% Owner |
– – • |
2021-04-27 |
4 |
B |
$17.00 |
$17,425,000 |
D/D |
1,025,000 |
1,175,000 |
2.45 |
- |
|
| Radovich Peter |
Director |
– • – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
I/I |
8,796 |
8,796 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-26 |
4/A |
B |
$14.90 |
$408,478 |
D/D |
27,413 |
88,226 |
2.44 |
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-26 |
4 |
A |
$14.90 |
$408,478 |
D/D |
27,413 |
88,226 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-23 |
4/A |
B |
$15.93 |
$18,694,901 |
D/D |
1,105,896 |
86,479 |
2.44 |
- |
|
| Berger Franklin M |
Director |
– • – |
2021-04-23 |
4 |
B |
$15.78 |
$2,118,900 |
D/D |
125,000 |
125,000 |
2.39 |
- |
|
| Mva Investors, Llc |
Director |
– • • |
2021-04-23 |
4 |
B |
$15.58 |
$2,423,250 |
I/I |
150,000 |
150,000 |
2.25 |
- |
|
| Lewis Joseph |
10% Owner |
– – • |
2021-04-23 |
4 |
B |
$15.58 |
$2,423,250 |
D/D |
150,000 |
150,000 |
2.45 |
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,578,262 |
286,691 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-23 |
4 |
A |
$15.93 |
$18,694,901 |
D/D |
1,105,896 |
86,479 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2021-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
217,033 |
17,390 |
|
- |
|
| Doebele Robert |
EVP, Chief Scientific OfficerO |
• – – |
2021-04-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
463,005 |
|
- |
|
| Vellanki Avanish |
President and CEOOfficer |
• • – |
2021-04-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
138,901 |
|
- |
|
| Vellanki Avanish |
President and CEOOfficer |
• • – |
2021-04-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,361,329 |
|
- |
|
67 Records found
|
|
Page 3 of 3 |
|
|
